ENGLISH


ipertesto
marcatori
immunoistochimici


ipertesto
neoplasie



performance
tecnica - P***


valore
diagnostico



CD11c

(scheda a cura di Marco Chilosi e Maria Grazia Zorzi)

Proteina appartenente alla famiglia delle beta2-integrine, espressa dalle cellule del sistema monocito-macrofagico.
Fa parte dell’eterodimero CD11c/CD18, con funzione di recettore del complemento (CR4).

Performance Tecnica P***

Anticorpo

Antigene

Valore Diagnostico **

RETRIEVAL:


DISTRIBUZIONE NEI TESSUTI NORMALI

  • Istiociti

    Monociti
    Macrofagi
  • Cellule dendritiche



APPLICAZIONI IN PATOLOGIA

  • Caratterizzazione dei processi proliferativi di natura istiocitaria o a cellule dendritiche
    Malattia di Rosai-Dorfman
    Leucemie mielo-monocitiche
    Istiocitosi a cellule di Langerhans

  • Caratterizzazione dei processi linfoproliferativi B
    Hairy-cell leukemia (HCL)


PROCESSI PROLIFERATIVI DI NATURA ISTIOCITARIA

EE

CD11c


S100


CD16


Caso 1. Malattia di Rosai-Dorfman (istiocitosi dei seni con linfoadenopatia massiva).
Nei seni linfonodali sono presenti elementi istiocitari, con nucleo ovalare, vescicoloso, frequentemente nucleolato, che inglobano linfociti o polimorfonucleati (“emperipolesi”). Tali cellule coesprimono marcatori macrofagici (CD11c, CD16) e proteina S-100.

BIBLIOGRAFIA

Histopathology. 1987 Nov;11(11):1181-91.
Langerhans cell histiocytosis: an unusual case illustrating the value of immunohistochemistry in diagnosis.
Hall PA, O'Doherty CJ, Levison DA.
Department of Histopathology, St Bartholomew's Hospital, London, UK.

The morphological features of Langerhans cell histiocytosis (histiocytosis X) are characteristic but the diagnosis can on occasion be difficult. A case is presented that illustrates the diagnostic value of immunohistochemistry in the differential diagnosis of this condition. The cells of Langerhans cell histiocytosis were found to express CD1, CD4, CD11b and CD11c. They also reacted with EBM11, UCHM1, KB61 and HLA-DR. Occasional cells showed nuclear staining with Ki67, but no other lymphoid antigens were detected. Immunoreactivity of the cells of Langerhans cell histiocytosis with antibodies that recognize antigens present on macrophages provides further evidence for immunological similarities between these cell types.


J Cutan Pathol. 1993 Aug;20(4):368-74.
Sinus histiocytosis (Rosai-Dorfman disease) clinically limited to the skin. An immunohistochemical and ultrastructural study.
Perrin C, Michiels JF, Lacour JP, Chagnon A, Fuzibet JG.
Department of Pathology, University of Nice, France.

A case study of sinus histiocytosis of Rosai-Dorfman (SH) clinically limited to the skin is presented with immunohistochemical study of the infiltrate, in both paraffin and cryostat sections. Factor XIIIa, a dendrocyte marker, was demonstrated in the cytoplasm of histiocytes. This feature had not been previously reported in this disease. In addition, the cells expressed S100 protein, CD4, CD1a, CD68, and CD11c. This immunophenotyping study suggests that SH could affect the antigen-presenting activity of Factor XIIIa cells, i.e., the skin dermal dendrocyte.


Am J Clin Pathol. 1994 Jul;102(1):45-54.
Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study.
Lauritzen AF, Delsol G, Hansen NE, Horn T, Ersboll J, Hou-Jensen K, Ralfkiaer E.
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark.

Eight histiocytic sarcomas, identified by examination of more than 2000 malignant lymphomas, are described. For comparison, tumor infiltrates from five monoblastic leukemias were also analyzed. The histiocytic sarcomas were all high-grade malignancies consisting of markedly pleomorphic large cells with many mitotic figures. At presentation, six of the patients had systemic symptoms (fever, fatigue, loss of weight), skin infiltrates, and lymphadenopathy. Despite aggressive chemotherapy, clinical remissions were short, and six patients died of disease .5-48 months (mean, 6.5 months) after diagnosis. The remaining two patients are alive and in partial or complete remission 7 and 12 months after diagnosis. Immunotypic examination showed that all the histiocytic sarcomas were positive for macrophage-related antigens and negative for antigens on B cells, T cells, myeloid cells, epithelial cells, and melanocytes. T-cell receptor and immunoglobulin genes were studied in three cases and were present in a germline configuration. One of the histiocytic sarcomas resembled Langerhans' cells in phenotype and morphology; it was classified as a Langerhans' cell sarcoma. The remaining histiocytic sarcomas did not express accessory cell-associated antigens, but more closely resembled "ordinary" tissue macrophages; they were positive for lysozyme and/or CD68, followed in frequency by CD11c, CD4, CD11b, CDw32, peanut agglutinin receptor, and CD13. Similar features were seen in the monoblastic leukemias. These conditions could only be distinguished from histiocytic sarcoma by clinical and morphologic, rather than immunophenotypic, criteria. Expression of oncoprotein p53 was studied in nine cases and was positive in six of six histiocytic sarcomas and one of three monoblastic leukemias. Rare malignancies show features consistent with the derivation from macrophages. Two entities may be distinguished: those that resemble antigen-presenting accessory cells and those that more closely resemble ordinary tissue macrophages. Recognition of these tumors is important clinically and requires assessment of clinical, morphologic, and immunophenotypic features, supplemented by analysis of T-cell receptor and immunoglobulin genes. Whether (or how) p53 gene mutations are implicated in their pathogenesis will be an important topic for future investigation.